The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
Primary Hyperoxaluria Type 1
The purpose of this study is to describe the natural history and progression of patients diagnosed with PH1, and to characterize the long-term real-world safety and effectiveness of lumasiran.
BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)
-
Clinical Trial Site, Phoenix, Arizona, United States, 85016
Clinical Trial Site, Washington, District of Columbia, United States, 20010
Clinical Trial Site, Boston, Massachusetts, United States, 02115
Clinical Trial Site, Rochester, Minnesota, United States, 55905
Clinical Trial Site, Cincinnati, Ohio, United States, 45229
Clinical Trial Site, Pittsburgh, Pennsylvania, United States, 15213
Clinical Trial Site, Dallas, Texas, United States, 75390
Clinical Trial Site, Houston, Texas, United States, 77030
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Alnylam Pharmaceuticals,
Medical Director, STUDY_DIRECTOR, Alnylam Pharmaceuticals
2028-09-01